Zero Benefit seen from use of Aducanumab

The latest review of Aducanumab (Aduhelm), the recently FDA approved medication for Alzheimer's, has been determined to have ​'Zero Benefit' as determined by the California Technology Assessment Forum in a recent report to the  Institute for Clinical and Economic Review (ICER). The stunningly depressing and ironic fact is that the report decries the lack of effective medications for Alzheimer's while not considering supporting treatment alternatives, e.g., transcranial infrared photobiomodulation, that have published clinical efficacy in reversing both cognitive and behavioral symptoms in subjects diagnosed with mild to moderate dementia. 

Hopefully more people will recognize that there are options available to influence the slope of decline as well as taking steps to prevent disease onset using what are considered 'alternative' approaches like those advocated by Dale Bredesen and Apollo Health (https://www.apollohealthco.com/). Quietmind Foundation is proud to have been invited to partner with Apollo Health in advocating for the development of noninvasive, non-drug treatment protocols for Alzheimer's and other neurodegenerative disorders. 

Link to the Medscape article: zero benefit to dementia patients while costing $56,000/yr.